Roche Adds To Its Immuno-Oncology Investments With Inovio Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss pharma licenses rights to a pair of preclinical, multi-antigen DNA immunotherapies for prostate cancer and hepatitis B, as well as delivery technology. Inovio gets $10 million up front and can earn milestones up to $412.5 million.